Covered recipient · General Payments record
MATTHEW JOSEPH RENDO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2019–2024
$593.01
- Reported across 14 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $303.65 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genmab U.S., Inc. | $132.50 | 1 |
| Merck Sharp & Dohme Corporation | $43.71 | 2 |
| TAIHO ONCOLOGY, INC. | $37.79 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.90 | 1 |
| Incyte Corporation | $20.02 | 1 |
| GlaxoSmithKline, LLC. | $19.37 | 1 |
| Gilead Sciences, Inc. | $16.07 | 1 |
| PFIZER INC. | $13.29 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Genmab U.S., Inc. | $132.50 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126829590 | CMS |
| Gilead Sciences, Inc. | $16.07 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803422 | CMS |
| GlaxoSmithKline, LLC. | $19.37 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115898320 | CMS |
| Incyte Corporation | $20.02 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141212513 | CMS |
| Merck Sharp & Dohme LLC | $21.09 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141817197 | CMS |
| Merck Sharp & Dohme LLC | $22.62 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141908402 | CMS |
| PFIZER INC. | $13.29 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131454199 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.90 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152180813 | CMS |
| TAIHO ONCOLOGY, INC. | $37.79 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137941026 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.